Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
6 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07300202 | A Phase I, Single-arm, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of Orialpha (BD-C) in Healthy Adult Volunteers | completed | Phase 1 | 15 | Oriplantee Company LimitedOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06027957 | CD19 CAR T-Cell Therapy for R/R Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia | completed | Phase 1 | 18 | Vinmec Research Institute of Stem Cell and Gene TechnologyOTHER | 1 | Aug 26, 2025 |
| clinicaltrials |
| NCT05520372 | Autologous Immune Enhancement Therapy (AIET) for Cancer Patients | completed | Phase 1 | 60 | Vinmec Research Institute of Stem Cell and Gene TechnologyOTHER | 1 | Aug 29, 2022 | clinicaltrials |
| NCT05301530 | Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients. | completed | Phase 1 | 50 | Nanogen Pharmaceutical Biotechnology Joint Stock CompanyINDUSTRY | 1 | Mar 29, 2022 | clinicaltrials |
| NCT04386343 | CH1701 for Prevention and Treatment of Radiation Burns(CH1701) | unknown | Phase 1 / Phase 2 | 92 | Vietlife Healthcare CorporationOTHER_GOV | 1 | Aug 24, 2020 | clinicaltrials |
| NCT03376503 | Nanogen Pegfilgrastim (Pegcyte) PK/PD Clinical Study in Breast Cancer Patients | completed | Phase 1 | 24 | Nanogen Pharmaceutical Biotechnology Joint Stock CompanyINDUSTRY | 1 | Dec 19, 2017 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials